Original articles
Hua Sang, Jiali Liu, Fang Zhou, Xiaofang Zhang, Jingwei Zhang, Yazhong Liu, Guangji Wang, Hui Ye. Target-responsive subcellular catabolism analysis for early-stage antibody-drug conjugates screening and assessment[J]. Acta Pharmaceutica Sinica B, 2021, 11(12): 4020-4031

Target-responsive subcellular catabolism analysis for early-stage antibody-drug conjugates screening and assessment
Hua Sanga,b, Jiali Liua, Fang Zhoua, Xiaofang Zhanga, Jingwei Zhanga, Yazhong Liua, Guangji Wanga, Hui Yea
a. Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China;
b. Department of Pharmacy, the Affiliated Hospital of Nantong University, Nantong 226001, China
Abstract:
Events including antibody-antigen affinity, internalization, trafficking and lysosomal proteolysis combinatorially determine the efficiency of antibody–drug conjugate (ADC) catabolism and hence the toxicity. Nevertheless, an approach that conveniently identifies proteins requisite for payload release and the ensuing toxicity for mechanistic studies and quality assessment is lacking. Considering the plethora of ADC candidates under development, we developed a target-responsive subcellular catabolism (TARSC) approach that examines ADC catabolism and probes changes in response to targeted interferences of proteins of interest. We firstly applied TARSC to study the commercial T-DM1 and the biosimilar. We recorded unequivocal catabolic behaviors regardless of the absence and presence of the targeted interferences. Their negligible differences in TARSC profiles agreed with their undifferentiated anti-tumoral efficacy according to further in vitro viability and in vivo tumor growth assays, highlighting TARSC analysis as a useful tool for biosimilarity assessment and functional dissection of proteins requisite for ADC catabolism. Additionally, we employed TARSC to investigate the catabolic behavior of a new trastuzumab–toxin conjugate. Collectively, TARSC can not only characterize ADC catabolism at (sub)cellular level but also comprehensively determine which protein targets affect payload release and therapeutic outcomes. Future use of TARSC is thus anticipated in early-stage screening, quality assessment and mechanistic investigations of ADCs.
Key words:    ADC    Target-responsive subcellular catabolism (TARSC)    T-DM1    Therapeutic efficacy    Screening    Biosimilarity   
Received: 2021-04-02     Revised: 2021-05-08
DOI: 10.1016/j.apsb.2021.05.024
Funds: We acknowledge the financial support of the Natural Science Foundation of Jiangsu Province (BK20180079 and BK20180558, China), the Leading Technology Foundation Research Project of Jiangsu Province (BK20192005, China), the National Natural Science Foundation of China (82173783, 82173882, 81803625), Six Talent Peaks Project in Jiangsu Province (SWYY-101, China), International Industrial Technology Research Collaboration of Nanjing (201911008, China), the Innovative Research Groups of the National Nature Science Foundation of China (81421005), Nantong Science and Technology Project (JC2019133, JCZ18131, China) and the Innovation Team of Affiliated Hospital of Nantong University (TFCT-A05, China).
Corresponding author: Guangji Wang,E-mail:guangjiwang@hotmail.com;Hui Ye,E-mail:cpuyehui@cpu.edu.cn     Email:guangjiwang@hotmail.com;cpuyehui@cpu.edu.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Hua Sang
Jiali Liu
Fang Zhou
Xiaofang Zhang
Jingwei Zhang
Yazhong Liu
Guangji Wang
Hui Ye

References:
[1] Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 2015; 35: e00225
[2] Yan H, Endo Y, Shen Y, Rotstein D, Dokmanovic M, Mohan N, et al. Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity. Mol Cancer Ther 2016; 15: 480-490
[3] Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 2014; 53: 3796-3827
[4] Chalouni C, Doll S. Fate of antibody-drug conjugates in cancer cells. J Exp Clin Cancer Res 2018; 37: 20
[5] Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev 2019; 48: 4361-4374
[6] Hedrich WD, Fandy TE, Ashour HM, Wang H, Hassan HE. Antibody-drug conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. Clin Pharmacokinet 2018; 57: 687-703
[7] Lee MV, Kaur S, Saad OM. Conjugation site influences antibody-conjugated drug pk assays: case studies for disulfide-linked, self-immolating next-generation antibody drug conjugates. Anal Chem 2020; 92: 12168-12175
[8] Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 2017; 16: 315-337
[9] Lyon R. Drawing lessons from the clinical development of antibody-drug conjugates. Drug Discov Today Technol 2018; 30: 105-109
[10] Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD-30auristatin conjugates. J Biol Chem 2006; 281: 10540-10547
[11] Li F, Ulrich M, Jonas M, Stone IJ, Linares G, Zhang X, et al. Tumor-associated macrophages can contribute to antitumor activity through fcγR-mediated processing of antibody-drug conjugates. Mol Cancer Ther 2017; 16: 1347-1354
[12] Lv C, Yang C, Ding D, Sun Y, Wang R, Han D, et al. Endocytic pathways and intracellular transport of aptamer-drug conjugates in live cells monitored by single-particle tracking. Anal Chem 2019; 91: 13818-13823
[13] Rago B, Tumey LN, Wei C, Barletta F, Clark T, Hansel S, et al. Quantitative conjugated payload measurement using enzymatic release of antibody-drug conjugate with cleavable linker. Bioconjug Chem 2017; 28: 620-626
[14] Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, et al. Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates. J Am Chem Soc 2016; 138: 1430-1445
[15] Bessire AJ, Ballard TE, Charati M, Cohen J, Green M, Lam MH, et al. Determination of antibody-drug conjugate released payload species using directed in vitro assays and mass spectrometric interrogation. Bioconjug Chem 2016; 27: 1645-1654
[16] Sang H, Lu G, Liu Y, Hu Q, Xing W, Cui D, et al. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. Anal Chim Acta 2017; 955: 67-78
[17] Liu Y, Zhou F, Sang H, Ye H, Chen Q, Yao L, et al. LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). J Pharm Biomed Anal 2017; 137: 170-177
[18] Schroder B, Saftig P. Intramembrane proteolysis within lysosomes. Ageing Res Rev 2016; 32: 51-64
[19] Cocchiaro P, Pasquale VD, Morte RD, Tafuri S, Avallone L, Pizard A, et al. The multifaceted role of the lysosomal protease cathepsins in kidney disease. Front Cell Dev Biol 2017; 5: 114
[20] He J, Yu S, Yee S, KaurK S. Xu K. Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry. MAbs 2018; 10: 960-967
[21] Singh AP, Guo L, Verma A, Wong GG, Thurber GM, Shah DK. Antibody coadministration as a strategy to overcome binding-site barrier for adcs: a quantitative investigation. AAPS J 2020; 22: 28
[22] Wymant JM, Sayers EJ, Muir D, Jones AT. Strategic trastuzumab mediated crosslinking driving concomitant HER2 and HER3 endocytosis and degradation in breast cancer. J Cancer 2020; 11: 3288-3302
[23] Miao R, Li M, Zhang Q, Yang C, Wang X. An ECM-to-Nucleus signaling pathway activates lysosomes for C. elegans larval development. Dev Cell 2020; 52: 21-37.e25
[24] Kissing S, Hermsen C, Repnik U, Nesset CK, Bargen KV, Griffiths G, et al. Vacuolar atpase in phagosome-lysosome fusion. J Biol Chem 2015; 290: 14166-14180
[25] Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006; 17: 114-124
[26] Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006; 66: 4426-4433
[27] Dong L, Li C, Locuson C, Chen S, Qian MG. A two-step immunocapture LC/MS/MS assay for plasma stability and payload migration assessment of cysteine-maleimide-based antibody drug conjugates. Anal Chem 2018; 90: 5989-5994
[28] Niemikoski H, Koske D, Kammann U, Lang T, Vanninen P. Studying the metabolism of toxic chemical warfare agent-related phenylarsenic chemicals in vitro in cod liver. J Hazard Mater 2020; 391: 122221
[29] Guo J, Wang T, Wu T, Zhang K, Yin W, Zhu M, et al. Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor. Eur J Med Chem 2020; 186: 111878
[30] Huang Y, Nagro CJ, Balic K, Mylott WR, Ismaiel OA, Ma E, et al. Multifaceted bioanalytical methods for the comprehensive pharmacokinetic and catabolic assessment of MEDI3726, an anti-prostate-specific membrane antigen pyrrolobenzodiazepine antibody-drug conjugate. Anal Chem 2020; 92: 11135-11144
[31] Tsui CK, Barfield RM, Fischer CR, Morgens DW, Li A, Smith BA, et al. CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity. Nat Chem Biol 2019; 15: 949-958
[32] Rios-Luci C, Garcia-Alonso S, Diaz-Rodriguez E, Nadal-Serrano M, J. Arribas J, Ocana A, et al. Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res 2017; 77: 4639-4651
[33] Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 2014; 16: 209
[34] Pegram MD, Miles D, Tsui CK, Zong Y. HER2-overexpressing/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors. Clin Cancer Res 2020; 26: 775-786
[35] Shah DK, Loganzo F, Haddish-Berhane N, Musto S, Wald HS, Barletta F, et al. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach. J Pharmacokinet Pharmacodyn 2018; 45: 339-349
[36] Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, et al. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn 2013; 40: 557-571
[37] Khera E, Thurber GM. Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody-drug conjugates. BioDrugs 2018; 32: 465-480
Similar articles: